Stereotactic ablative radiation therapy for spinal metastases: experience at a single Brazilian institution

This study aims to assess the clinical outcomes of patients with spine metastases who underwent stereotactic ablative radiation therapy (SABR) as part of their treatment. SABR has arisen as a contemporary treatment option for spinal metastasis patients with good prognoses. Between November 2010 and...

Full description

Saved in:

Bibliographic Details
Published in:	Reports of practical oncology and radiotherapy Vol. 26; no. 5; pp. 756 - 763
Main Authors:	Marta, Gustavo N, de Arruda, Fernando F, Miranda, Fabiana A, Silva, Alice R N S, Neves-Junior, Wellington F P, Mancini, Anselmo, Hanna, Samir A, Abreu, Carlos E C V, da Silva, João Luis F, Nascimento, Jose Eduardo V, Haddad, Cecília Maria K, Moraes, Fabio Y, Gadia, Rafael
Format:	Journal Article
Language:	English
Published:	Poland Via Medica 01-01-2021
Subjects:	Research Paper treatment stereotactic body radiation therapy spine metastases radiation therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This study aims to assess the clinical outcomes of patients with spine metastases who underwent stereotactic ablative radiation therapy (SABR) as part of their treatment. SABR has arisen as a contemporary treatment option for spinal metastasis patients with good prognoses. Between November 2010 and September 2018, Spinal SABR was performed in patients with metastatic disease in different settings: radical (SABR only), postoperative (after decompression and/or fixation surgery), and reirradiation. Local control (LC), pain control, overall survival (OS) and toxicities were reported. Eighty-five patients (corresponding to 96 treatments) with spine metastases were included. The median age was 59 years (range, 23-91). In most SA BR (82.3%, n = 79) was performed as the first local spine treatment, while in 12 settings (12.5%), fixation and/or decompression surgery was performed prior to SABR. Two-year overall survival rate was 74.1%, and median survival was 19 months. The LC rate at 2 years was 72.3%. With regard to pain control, among 67 patients presenting with pain before SA BR, 83.3% had a complete response, 12.1% had a partial response, and 4.6% had progression. Vertebral compression fractures occurred in 10 patients (11.7%), of which 5 cases occurred in the reirradiation setting. Radiculopathy and myelopathy were not observed. No grade III or IV toxicities were seen. This is the first study presenting a Brazilian experience with spinal SA BR, and the results confirm its feasibility and safety. SABR was shown to produce good local and pain control rates with low rates of adverse events.
ISSN:	1507-1367 2083-4640
DOI:	10.5603/RPOR.a2021.0086